SCHEMBL30537191

SCHEMBL30537191

Cc1ncc(-c2nc(N[C@H]3CCN(S(=O)(=O)c4cnn(C)c4)C[C@H]3F)ncc2C(F)(F)F)s1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 19/20 0.54
▸ CDK2 P24941 19/20 0.54
▸ CCND1 P24385 12/20 0.54
▸ CDK6 Q00534 12/20 0.54
▸ CDK1 P06493 11/20 0.54
▸ CCNB1 P14635 11/20 0.54
▸ CDK4 P11802 10/20 0.54
▸ CCND3 P30281 10/20 0.54
▸ CCNT1 O60563 3/20 0.54
▸ CDK7 P50613 3/20 0.54
▸ CDK9 P50750 3/20 0.54
▸ CCNH P51946 3/20 0.54
▸ MNAT1 P51948 3/20 0.54
▸ CCNB2 O95067 1/20 0.37
▸ CCNE2 O96020 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ CDK5R1 Q15078 1/20 0.37
▸ CCNB3 Q8WWL7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25434367 1.00 CCNE1 (0.54) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30537157 1.00 CCNE1 (0.54) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL25434162 1.00 CCNE1 (0.54) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30838018 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL25433564 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30838005 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL25433680 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL25434177 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL25434420 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30838080 0.89 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 — — WO claimed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US disclosed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CCNE1 36/4885CDK2 4/4885CCND1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback